Profil
Timothy E.
Woenker is currently the Chief Operating Officer & Director at Novilytic LLC.
Postes actifs de Timothy E. Woenker
| Sociétés | Poste | Début |
|---|---|---|
Novilytic LLC
 Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Directeur des opérations | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Novilytic LLC
Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Health Services |
